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Abstract
B-cells, in addition to antibody secretion, have emerged increasingly as effector and immu-
noregulatory cells in several chronic inflammatory diseases. Although Erythema Nodosum
Leprosum (ENL) is an inflammatory complication of leprosy, the role of B- cell subsets has
never been studied in this patient group. Therefore, it would be interesting to examine the
contribution of B-cells in the pathogenesis of ENL. A case-control study design was used
to recruit 30 untreated patients with ENL and 30 non-reactional lepromatous leprosy (LL)
patient controls at ALERT Hospital, Ethiopia. Peripheral blood samples were obtained
before, during and after treatment from each patient. Peripheral blood mononuclear cells
(PBMCs) were isolated and used for immunophenotyping of B- cell subsets by flow cytome-
try. The kinetics of B-cells in patients with ENL before, during and after Prednisolone treat-
ment of ENL was compared with LL patient controls as well as within ENL group. Total B-
cells, mature B-cells and resting memory B-cells were not significantly different between
patients with ENL reactions and LL controls before treatment. Interestingly, while the per-
centage of naive B-cells was significantly lower in untreated ENL patients than in LL patient
controls, the percentage of activated memory B-cells was significantly higher in these
untreated ENL patients than in LL controls. On the other hand, the percentage of tissue-like
memory B-cells was considerably low in untreated ENL patients compared to LL controls. It
appears that the lower frequency of tissue-like memory B-cells in untreated ENL could pro-
mote the B-cell/T-cell interaction in these patients through downregulation of inhibitory mole-
cules unlike in LL patients. Conversely, the increased production of activated memory B-
cells in ENL patients could imply the scale up of immune activation through antigen presen-
tation to T-cells. However, the generation and differential function of these memory B-cells
need further investigation. The finding of increased percentage of activated memory B-cells
in untreated patients with ENL reactions suggests the association of these cells with the
ENL pathology. The mechanism by which inflammatory reactions like ENL affecting these
memory cells and contributing to the disease pathology is an interesting area to be ex-
plored for and could lead to the development of novel and highly efficacious drug for ENL
treatment.
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Author summary
Some leprosy patients develop reactions which cause a significant morbidity and mortality
in leprosy patients. There are two types of leprosy reactions, type 1 and type 2 reactions.
Type 2 or Erythema nodosum leprosum (ENL) is an immune-mediated inflammatory
complication of leprosy which occurs in lepromatous and borderline lepromatous leprosy
patients. The exact cause of ENL is unknown. Immune-complexes and T-cells are sug-
gested as the aetiology of ENL. However, the contribution of B-cells in ENL reactions has
never been addressed. In the present study we described the role of B-cell subsets in ENL
reaction and compared with non reactional LL patient controls before, during and after
corticosteroids treatment. We found increased antigen experienced and activated B-cells
in untreated ENL patients compared to those without the reaction (LL patients). This
implies that B-cells are associated with ENL pathology. Therefore, the finding provides a
ground for future research targeting B-cells to develop effective drug for ENL treatment.
Introduction
B-cells enable the antigen-specific humoral immunity by forming highly specific antibodies
during primary immune response. B-cells within the lymphoid tissue of the body such as bone
marrow, spleen and lymph nodes, are stimulated by antigenic substances to proliferate and
transform into plasma cells and the plasma cells in turn produce immunoglobulins which bind
to cognate antigen [1]. Although B-cells are traditionally known as precursors for antibody-
secreting plasma cells, they may also act as antigen-presenting cells (APC) and play an impor-
tant role in the initiation and regulation of T and B cell responses [1, 2]. However, B-cells may
also involve in disease pathology especially in autoimmune disorders. The pathogenic roles of
B-cells in autoimmune diseases occur through several mechanistic pathways that include auto-
antibodies, immune-complexes, dendritic and T-cell activation, cytokine synthesis, chemo-
kine-mediated functions, and ectopic neolymphogenesis [2].
Memory B-cells are B-cell sub-types that are formed within the germinal centres following
primary infection and are important in generating an accelerated and more robust antibody-
mediated immune response in the case of re-infection also known as a secondary immune
response. Recent advances in tracking antigen-experienced memory B-cells have shown the
existence of different classes of memory B-cells that have considerable functional differences.
Currently there are three types of memory B-cells: resting, activated and tissue like memory
B-cells, [3]. Activated memory B-cells have been shown to function as effective antigen pre-
senting cells (APCs) to naive T-cells [4]. Tissue-like memory B-cells (TLM) expressed patterns
of homing and inhibitory receptors similar to those described for antigen-specific T-cell
exhaustion. Tissue like memory B-cells proliferate poorly in response to B-cell stimuli, which
is consistent with high-level expression of multiple inhibitory receptors. Higher percentage of
TLM has been reported in immunosuppressive diseases such as HIV [5, 6].
Leprosy is a spectrum disease with the polar tuberculiod (TT) and lepromatous (LL) forms
and the three borderlines forms including borderline tuberculoid (BT), mid borderline (BB)
and borderline lepromatous (BL) [7]. TT characterized by strong cell-mediated immune
response which restricts the spread of M. leprae while the LL forms are characterized by lack of
cell mediated immune response which allows the growth and spread of M. leprae in these
patients [8]. Studies have shown that circulating high levels of antibodies to M.leprae specific
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antigens in LL patients although these antibodies are unable to control the growth and the
spread of M.leprae [9].
The study of the humoral immunity in leprosy has largely been restricted to antibodies.
Patients towards lepromatous leprosy (LL) pole of the spectrum have higher antibody concen-
tration as compared with the tuberculoid (TT) pole. Elevation of the polyclonal isotypes of
these classes of antibody types with the highest concentration has reported in patients with LL
forms compared to the other clinical types of the spectrum [10–13]. However, the role of these
antibodies in the pathogenesis of leprosy is poorly understood.
Although the in-situ presences of plasma cells and B-cells have been reported in leprosy, the
role of these cells in the pathology of leprosy lesions is unclear. Both Plasma cells and B-cells
have been detected in tuberculoid and lepromatous leprosy lesions [14]. It was speculated that
these lesional B-cells could influence T-cell responses and /or play a role in maintaining the
inflammatory reaction in leprosy partly through the local secretion of antibodies. However,
data supporting such hypothesis are lacking. It is generally thought that antibodies against M.
leprae components do not play a significant role in protection against leprosy. However, anti-
bodies may play a role in the uptake of M. leprae by mononuclear phagocytes and hence the
pathogenesis of the diseases [15].
There are two types of leprosy reaction, type one and erythema nodosum leprosum (ENL)
reactions. ENL is an immune-mediated inflammatory complication affecting about 50% of
patients with lepromatous leprosy (LL) and 10% of borderline lepromatous (BL) patients [16–
18]. ENL can occur before, during or after successful completion of multi-drug therapy (MDT).
The onset of ENL is acute, but it may pass into a chronic phase and can be recurrent [19].
B -cells are the least studied immune cells in leprosy in general and leprosy reactions in par-
ticular. An increased percentage and absolute count of B-cells in the sera from patients with
ENL has been reported [20], but normal numbers of circulating B-cells have also been reported
[21]. A study looking at T-cell phenotypes in ENL lesions showed a normal proportion of B-
cells in these patients [22]. In a prospective cohort study of 13 untreated patients with acute
ENL reaction, polyclonal IgG1 antibody synthesis was elevated compared to patients with sta-
ble lepromatous leprosy and decreased after the disease had subsided. However, the concentra-
tion of polyclonal IgG2 had revealed the reverse trend: decreased before treatment and
increased after treatment [23]. These authors also investigated the frequency of antibody
secreting B-cells in the blood compartment of these patients with the Enzyme-Linked Immu-
noSpot (ELISPOT) and found that the decrease in M. leprae specific IgG1 antibody was not
related to the down-regulation of B-cell responses.
In addition to antibody secretion, B-cells have emerged increasingly as both effector and
immunoregulatory cells in several chronic inflammatory diseases [24]. The role of B-cells in
the pathogenesis of autoimmune disorders such as rheumatoid arthritis (RA) and systemic
lupus erythematosus (SLE) is now being re-examined [1]. It would therefore be interesting to
examine the contribution of B-cells in the pathogenesis of ENL.
Materials and methods
Ethics statement
Informed written consent for blood and skin biopsies were obtained from patients following
approval of the study by the Institutional Ethical Committee of London School of Hygiene and
Tropical Medicine, UK, (#6391), AHRI/ALERT Ethics Review Committee, Ethiopia (P032/12)
and the National Research Ethics Review Committee, Ethiopia (#310/450/06). Under 18 years
old patients were excluded from the study. Vulnerable and minor groups were also excluded
from the study. All patient data analyzed and reported anonymously.
B-cells in ENL reactions
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Study design
A case-control study with follow-up after the initiation of prednisolone treatment was used to
recruit 30 untreated patients with ENL reactions and 30 non-reactional LL patient controls
between December 2014 and January 2016 at ALERT Hospital, Ethiopia.
Patient recruitment
All patients recruited into this study were attending the ALERT Hospital, Addis Ababa, Ethio-
pia. The patients were classified clinically and histologically on the leprosy spectrum based on
the Ridley-Jopling (RG) classification schemes [7]. ENL was clinically diagnosed when a
patient with BL or LL leprosy had painful crops of tender cutaneous erythematous skin lesions
[17]. New ENL was defined as the occurrence of ENL for the first time in a patient with LL or
BL. Lepromatous leprosy was clinically diagnosed when a patient had widely disseminated
nodular lesions with ill-defined borders and BI above 2 [19]. Patients with ENL were treated
according to the World Health Organization (WHO) treatment guideline with steroids that
initially consisted of 40mg oral prednisolone daily and the dose was tapered by 5mg every fort-
night for 24 weeks. All patients were received WHO-recommended leprosy multidrug treat-
ment (MDT).
Blood sample collection and PBMC isolation
Twenty micro-litter of venous blood was collected into sterile BD heparinised vacutainer tubes
(BD, Franklin, Lakes, NJ, USA) before treatment, during treatment on week 12 and after treat-
ment on week 24 from each patient and used for PBMC isolation. PBMCs were separated by
density gradient centrifugation at 800g for 25 min on Ficoll-Hypaque (Histopaque, Sigma
Aldrich, UK) as described earlier [25]. Cells were washed three times in sterile 1x phosphate
buffered saline (PBS, Sigma Aldrich, UK) and re-suspended with 1mL of Roswell Park Memo-
rial Institute (RPMI medium 1640 (1x) + GlutaMAX+ Pen-Strip GBICO, Life technologies,
UK). Cell viability was determined by 0.4% sterile Trypan Blue solution (Sigma Aldrich, UK)
ranged from 94–98%. PBMC freezing was performed using a cold freshly prepared freezing
medium composed of 20% Foetal Bovine Serum (FBS, heat inactivated, endotoxin tested5
EU/ml, GIBCO Life technologies, UK), 20% dimethyl sulphoxide (DMSO) in RPMI medium
1640 (1x). Cells were kept at -80˚C for 2–3 days and transferred to liquid nitrogen until use.
Cell thawing was done as described [26]. The procedure is briefly described as: cells were incu-
bated in a water bath (37˚C) for 30 to 40 seconds until thawed half way and re-suspended in
10% FBS in RPMI medium 1640 (1x) (37˚C) containing 1/10,000 benzonase until completely
thawed, washed 2 times (5 minutes each) and counted. The percentage viability obtained was
above 90%.
Surface staining for flow cytometry
Cells were harvested, transferred to round bottomed FACS tubes (Falcon, BD, UK) and
washed twice at 400g for 5 minutes at room temperature. The cells were resuspended in 50μl
of PBS and incubated in 1ml of 10% human AB serum (Sigma Aldrich, UK) for 10 minutes in
the dark at room temperature to block nonspecific Fc-mediated interactions, and centrifuged
at 400g for 5 minutes. After resuspending cells in 50μL PBS buffer, Life/dead staining was per-
formed at a concentration of 1μl /1mL live/dead stain (V500 Aqua, Invitrogen, Life technolo-
gies, UK) for 15 minutes at 4˚C in the dark. Cells were washed once and stained for surface
markers directed against CD10 (FITC), CD19 (PerCp-Cy5.5), CD27 (V500), CD21 (V450)
and Isotype control (IgG1) (all from BD Biosciences, UK), Live/dead (eFluoro 780, Invitrogen,
B-cells in ENL reactions
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Life technologies, UK). A single-stained OneComb eBeads (affymetrix, eBioscience, UK) for
all fluorescence compensation except for the live dead stain were used. For the viability dye,
cells rather than beads were stained and used for fluorescence compensation.
Sample acquisition and gating strategy
Forward scatter height (FSC-H) versus Forward scatter area (FSC-A) plots were used to select
singlets, and FSC-A versus dead cell marker plots identified viable cells. Side scatter area (SSC-
A) versus FSC-A plots were used to discriminate lymphocytes from monocytes and residual
granulocytes. The threshold for FSC was set to 5,000. For each sample, 500,000–1,000,000 cells
were acquired. The percentage of B-lymphocytes (CD19+), Mature B-cells (CD19+CD10-),
Nave B-cells (CD19+CD10-C27-CD21+), resting memory B- cells (CD19+CD10-CD27+CD21+),
activated memory B cells(CD19+CD10-CD27+CD21-) and tissue like memory B-cells
(CD19+CD10-CD27-CD21-) was defined relative to the parent population with FlowJo version
10 (Tree Star, USA) using logicle (bi-exponential) transformation as recommended [27, 28]
(Fig 1). Data were exported to Excel spreadsheet for each sample and compiled for further
analysis.
Statistical analysis
Differences in percentage of B-cell subsets were analyzed with either the two-tailed Mann-
Whitney U test or the Wilcoxon signed rank non-parametric tests using STATA 14 version 2
(San Diego California USA). Graphs were produced by GraphPad Prism version 5.01 for Win-
dows (GraphPad Software, San Diego California USA). The median and Hodges-Lehmann
estimator were used for result presentation. Hodges–Lehmann is used to measure the effect
size for non-parametric data [29]. P-values were corrected for multiple comparisons. The sta-
tistical significance level was set at p0.05.
Results
Total B- lymphocytes and mature B-cells
The median percentage of B-lymphocytes (CD19+) in patients with ENL (9.5%) and LL con-
trols (11.6%) was not statistically significantly different at recruitment. During treatment, the
percentage of B-cells slightly increased to 10% in patients with ENL and to 14% in LL patient
controls but did not show a statistically significant difference. However, after treatment, the
median percentage of B-cells appreciably decreased to 5.7% in patients with ENL while it was
slightly decreased in LL patient controls to 12.0% and the difference between the two groups
was statistically significantly different (P 0.001; ΔHL = 6.02%) (Fig 2A).
The kinetic analysis of B-lymphocytes within ENL group at different treatment time points
has shown that the median percentage of B-lymphocytes before and during treatment of
patients with ENL was 9.5% and 9.9% respectively (P>0.05). However, after treatment, the
percentage of these cells was significantly decreased to 5.7% compared with before and during
treatment (P 0.05) (Fig 2D).
The median percentage of mature (CD19+CD10-) and immature (CD19+CD10+) B-cells in
patients with ENL and LL controls before and after treatment were also measured. A signifi-
cant difference was not observed with regard to the median percentage of mature and imma-
ture B-cells in patients with ENL reactions and non-reactional LL patient controls before and
after treatment (Fig 2B). Similarly, the median percentage of mature B-cells before and after
treatment was not statistically significantly different within ENL group (Fig 2E).
B-cells in ENL reactions
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The median percentage of naive B-cells (CD19+CD10-CD27-CD21+) in untreated ENL
patients was significantly lower (76.0%) than in LL patient controls (86.4%) (Fig 2C). This
implies that more number of B-cells in untreated ENL patients are antigen experienced than
those from LL patient controls. On the other hand, the percentage of naive B-cells within ENL
group was not significantly changed before and after treatment (Fig 2F).
Fig 1. Gating strategy for B-cell sub populations; (1A) gating B-lymphocytes by FSCA versus CD19, (1B) gating
mature B-cells (CD19+CD10-), (1C) memory B-cells obtained by gating mature B-cells for CD27 versus CD21.
https://doi.org/10.1371/journal.pntd.0006121.g001
B-cells in ENL reactions
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Fig 2. The median percentage of total B-lymphocytes (CD19+), mature B-cells (CD19+CD10-) and naïve B-lymphocytes
(CD19+CD10-CD27-CD21+) in the PBMCs of) patients with ENL and LL controls before, during and after treatment respectively
(2A,2B,2C); within ENL patients before, during and after treatment respectively (2D,2E,2F). Statistical test: Mann-Whitney unpaired test (U)
(2A, 2B, 2C) and Wilcoxon matched-pairs signed rank test (2D, 2E, 2F). * P 0.05; ** P 0.005; ***P 0.001. Box and whiskers show
median ± interquartile range.
https://doi.org/10.1371/journal.pntd.0006121.g002
B-cells in ENL reactions
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Increased activated and decreased tissue like memory B-cells in
untreated ENL
The median percentage of memory B-cell subtypes (resting, activated and tissue-like memory
B-cells) in patients with ENL reactions and non-reactional LL controls as well as within ENL
group was analysed in the unstimulated PBMCs before, during and after treatment.
The median percentage of activated memory B-cells (CD19+ CD10-CD27+CD21-) was sig-
nificantly higher in patients with ENL (2.6%) than in LL patient controls (1.4%) before treat-
ment (P 0.005). During treatment, the percentage of activated memory B-cells (AM) in
patients with ENL and LL controls increased to 3.8% and 4.4% respectively and the difference
was not statistically significantly different (P> 0.05). After treatment, the percentage of these
memory cells did not change (Fig 3B).
A comparison within ENL has shown that the median percentage of activated memory B-
cells in untreated ENL patients was higher (2.6%) than after treatment (1.3%) and the differ-
ence was statistically significantly different (P 0.005) (Fig 3E). Hence, it seems that activated
memories B-cell is associated with ENL reactions.
The median percentage of resting memory B-cells (CD19+ CD10-CD27+CD21+) was 5.8%
in patients with ENL and 4.8% in LL patient controls before treatment and the result was not
statistically significantly different. However, during treatment it was increased to 15.2% in
patients with ENL and was higher than in LL patient controls (8.6%) (P0.05). After treat-
ment, the proportion of these memory cells was decreased to below 5% in both groups and
was not statistically significantly different (Fig 3A).
Analysis within ENL group has shown that the proportion of resting memory B-cells (RM)
was considerably lower (5.8%) before treatment than during treatment (15.3%) (P0.001).
After treatment, the proportion of these resting memory B-cells was decreased to 3.7% and it
was significantly lower than before and during treatment (P 0.05) (Fig 3D).
Interestingly, untreated ENL patients had significantly lower (5.2%) median percentage of
tissue-like memory B-cells (TLM) (CD19+CD10-CD27-CD21-) than the corresponding LL
patient controls (10.7%) (P0.05). However, after treatment a significant difference was not
observed between these two groups (Fig 3C). Similarly, comparison within ENL group has
shown that the median percentage of TLM is significantly lower in untreated ENL patients
than after treatment (P 0.05) (Fig 3F).
Discussion
Memory B-cells are subtypes of B-cells that are formed within the germinal centres following
infection. They proliferate and differentiate into antibody producing plasma cells also called
effector B-cells in response to re-infection. Memory B-cells rapidly differentiate into plasma-
blasts that produce class-switched antibodies which are capable of clearing the infection far
more quickly than naive B-cells [3]. The different classes of memory B-cells have been studied
in various chronic viral infections such as hepatitis and HIV and in several autoimmune dis-
eases [30, 31]. The role of B-cells in the pathogenesis of ENL has been speculated in several
studies but has never been studied. For the first time, we studied B-cells and the memory B-
cell sub-types in patients with ENL and LL controls at different time points (before, during
and after treatment) to investigate the dynamics of these cells during the course of predniso-
lone treatment.
The percentage of total B-cells was not significantly different in the two groups before treat-
ment. However, after treatment, the proportion of B-cells was significantly reduced from 9.5%
to 5.7% in patients with ENL. The reduction of B-cells after prednisolone treatment of patients
with ENL could be either transitory or associated with the subsiding of the ENL reaction
B-cells in ENL reactions
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Fig 3. The median percentage of resting memory B-cells (CD19+CD10-CD27+CD21+), activated memory B-cells
(CD19+CD10-CD27+CD21-) and tissue-like memory B-cells (CD19+CD10-CD27-CD21-) in the PBMCs of patients with ENL and LL
controls before, during and after treatment respectively (3A,3B,3C); within ENL patients before, during and after treatment
respectively (3D,3E,3F). Statistical test: Mann-Whitney unpaired test (U) (3A,3B, 3C)) and Wilcoxon matched-pairs signed rank test (3D, 3E,
3F)B). * P 0.05; ** P 0.005; ***P 0.001. Box and whiskers show median ± interquartile range.
https://doi.org/10.1371/journal.pntd.0006121.g003
B-cells in ENL reactions
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which needs further investigation. The success of Rituximab to deplete B-cells for the treat-
ment of rheumatoid arthritis has stimulated investigation of its effects in several other immune
disorders, and considerable interest in the potential of drugs that can modulate B-cell function
for the treatment of such diseases [32]. Thus, the finding of reduced B-cells after ENL subsides
poses the question whether depleting B-cells could be effective in the treatment of ENL.
Patients with ENL had a significantly lower naïve B-cells (76.0%) than LL controls (84.6%)
before treatment (P0.05; L-H = 6.75). It implies that more B-cells are antigen experienced in
untreated ENL patients compared to in LL patient controls. However, the proportion of naïve
B-cells was still unusually high in spite of the presence of abundant M. leprae antigens in these
patients.
A significant difference was not observed with regard to the frequency of resting memory B
cells (RM) in the two groups before treatment. However, the median percentage of activated
memory B-cells (AM) was significantly higher in patients with ENL (2.6%) than in LL controls
(1.4%) before treatment. Several studies have shown that activated memory B-cells are
increased in patients with disease flares in systemic lupus erythematosus (SLE) [33] and rheu-
matoid Arthritis [34]. However, the biology of ENL and autoimmune diseases is different and
whether activated memory B-cells are undesirable or not in the pathogenesis of ENL should be
further investigated to arrive at a conclusive evidence. Nevertheless, activated B-cells may be
primed to plasma B-cells which in turn produce immunoglobulins [30]. These immunoglobu-
lins could interact with the M.leprae antigen and thereby form excess immune-complexes
beyond clearance or activated B-cells may serve as antigen presenting cells i.e. presenting M.
leprae antigens to T-cells. Depending on the magnitude of antigen presentation, the T-cell
response could be excessive and may cause tissue damage.
Patients with ENL had lower percentage of tissue-like memory (TLM) B-cells (5.2%) than
LL controls (10.7%) before treatment. Several studies have indicated that TLM B-cells represent
the exhausted state of B-cells since they express several inhibitory receptors, including the
immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing inhibitory receptor Fc
receptor-like protein 4 (FcRL4) [35]. TLM B-cells show a reduced tendency to proliferate in
response to cognate antigen [36]. The expression of FcRL4 on human B-cell lines disrupts
immune synapse formation and blocks antigen induced B-cell receptor (BCR) signalling [37].
They also express not only FcRL4 but also a number of other inhibitory and chemokine recep-
tors that would reduce the likelihood of B and T cell interaction [5]. It has been shown that a
specific siRNA knockdown of FcRL4 and other inhibitory receptors may lead to a rescue of Ig
secretion and proliferation in these tissue-like memory B-cells [38]. In contrary to our findings,
increased proportion of TLM have been reported in chronic infections such as in hepatitis C
virus and malaria infections, and in certain autoimmune diseases [39, 40]. The decreasing ten-
dency of TLM and increased secretion of activated memory B-cells may indicate the activation
of B-cells when LL patients develop ENL reactions. The finding of increased percentage of TLM
in LL patients in this study may partly explain why B-cells are unable to control M.leprae multi-
plication in spite of their abundance in LL patients. The T-cell unresponsiveness in LL may also
be associated with the increased production of TLM B-cells. It appears that the higher frequency
of TLM B-cells in LL could alter the B-cell/T-cell interaction through blocking B-cell receptors
and this hypothesis could be a fertile area for future investigation. Once, this hypothesis is
proved, the search for the B-cell immunomodulators that safely overcome this exhaustion phe-
notype may be necessary in order to develop proper immune response to LL patients. On the
other hand, the significant reduction of TLM during ENL reaction suggests the down regulation
of inhibitory molecules and thereby increases immune activation in LL patients leading to the
onset ENL reaction. Thus, our finding implies that TLM B-cells could have a role in the initia-
tion of ENL reactions which is a new exciting area for further investigation.
B-cells in ENL reactions
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